Literature DB >> 23624623

Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma.

Sellam Karunanithi1, Punit Sharma, Abhishek Kumar, Bangkim Chandra Khangembam, Guru Pada Bandopadhyaya, Rakesh Kumar, Ajit Goenka, Deepak Kumar Gupta, Arun Malhotra, Chandrasekhar Bal.   

Abstract

OBJECTIVES: To compare the diagnostic accuracy of contrast enhanced magnetic resonance imaging (Ce-MRI) and (18)F-fluorodopa ((18)F-FDOPA) positron emission tomography (PET)-computed tomography (CT) for detecting recurrent glioma.
METHODS: In this prospective study, 35 patients (age, 36.62 ± 0.86 years; 80 % male) with histopathologically proven glioma with clinical suspicion of recurrence were evaluated using Ce-MRI and (18)F-FDOPA PET-CT. (18)F-FDOPA PET-CT images were evaluated qualitatively and semi-quantitatively. Combination of clinical follow-up (minimum 1 year), repeat imaging and/or biopsy (when available) was taken as the reference standard.
RESULTS: Based on the reference standard, 26 patients were positive and nine were negative for recurrence. The sensitivity, specificity and accuracy of Ce-MRI were 92.3 %, 44.4 % and 80 % respectively, whereas those of (18)F-FDOPA PET-CT were 100 %, 88.89 % and 97.1 % respectively. Results of Ce-MRI and (18)F-FDOPA PET-CT were concordant in 74.3 % (29/35) and discordant in 17.1 % of patients (6/35). On McNemar analysis the difference was not statistically significant overall (P = 0.687), for high-grade tumour (P = 0.5) or low-grade tumours (P = 1.0). However, (18)F-FDOPA PET-CT was more specific than Ce-MRI overall (P = 0.0002), for high-grade tumour (P = 0.006) and low-grade tumours (P = 0.004).
CONCLUSION: F-FDOPA PET-CT shows a high but comparable diagnostic accuracy to Ce-MRI for the detection of recurrent glioma. However, it is more specific than Ce-MRI. KEY POINTS: • Recurrent glioma in the postoperative site remains a diagnostic dilemma. • (18) F-FDOPA PET-CT shows high diagnostic accuracy for detecting recurrent glioma. • Diagnostic accuracies for (18) F-FDOPA PET-CT and contrast enhanced MRI are comparable. • However, (18) F-FDOPA PET-CT is more specific than Ce-MRI for recurrent glioma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23624623     DOI: 10.1007/s00330-013-2838-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  24 in total

1.  Amino acid assignment to one of three blood-brain barrier amino acid carriers.

Authors:  W H Oldendorf; J Szabo
Journal:  Am J Physiol       Date:  1976-01

2.  O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study.

Authors:  W A Weber; H J Wester; A L Grosu; M Herz; B Dzewas; H J Feldmann; M Molls; G Stöcklin; M Schwaiger
Journal:  Eur J Nucl Med       Date:  2000-05

3.  Aspects of 6-[18F]fluoro-L-DOPA preparation: precursor synthesis, preparative HPLC purification and determination of radiochemical purity.

Authors:  F Füchtner; P Angelberger; H Kvaternik; F Hammerschmidt; B Peric Simovc; J Steinbach
Journal:  Nucl Med Biol       Date:  2002-05       Impact factor: 2.408

4.  Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging.

Authors:  A I Holodny; S Makeyev; B J Beattie; S Riad; R G Blasberg
Journal:  AJNR Am J Neuroradiol       Date:  2010-02-11       Impact factor: 3.825

5.  18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.

Authors:  Wei Chen; Daniel H S Silverman; Sibylle Delaloye; Johannes Czernin; Nirav Kamdar; Whitney Pope; Nagichettiar Satyamurthy; Christiaan Schiepers; Timothy Cloughesy
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

6.  Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA.

Authors:  R E Yee; D W Cheng; S C Huang; M Namavari; N Satyamurthy; J R Barrio
Journal:  Biochem Pharmacol       Date:  2001-11-15       Impact factor: 5.858

Review 7.  Fluorinated amino acids for tumour imaging with positron emission tomography.

Authors:  Peter Laverman; Otto C Boerman; Frans H M Corstens; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-01-11       Impact factor: 9.236

8.  Failure of computerized tomography to differentiate between radiation necrosis and cerebral tumour.

Authors:  J R van Dellen; A Danziger
Journal:  S Afr Med J       Date:  1978-02-04

9.  Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors.

Authors:  L Ostergaard; F H Hochberg; J D Rabinov; A G Sorensen; M Lev; L Kim; R M Weisskoff; R G Gonzalez; C Gyldensted; B R Rosen
Journal:  J Neurosurg       Date:  1999-02       Impact factor: 5.115

10.  18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.

Authors:  Carlos J Ledezma; Wei Chen; Victor Sai; Bonnie Freitas; Tim Cloughesy; Johannes Czernin; Whitney Pope
Journal:  Eur J Radiol       Date:  2008-05-29       Impact factor: 3.528

View more
  15 in total

Review 1.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

2.  Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.

Authors:  Chani M Becker; Rajneet K Oberoi; Stephan J McFarren; Daniel M Muldoon; Deanna H Pafundi; Jenny L Pokorny; Debra H Brinkmann; John R Ohlfest; Jann N Sarkaria; David A Largaespada; William F Elmquist
Journal:  Neuro Oncol       Date:  2015-05-12       Impact factor: 12.300

3.  Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.

Authors:  Derek Richard Johnson; Chad Allan Glenn; Ramin Javan; Jeffrey James Olson
Journal:  J Neurooncol       Date:  2021-10-25       Impact factor: 4.130

4.  Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.

Authors:  Maria C Rossi Espagnet; Andrea Romano; Valeria Mancuso; Francesco Cicone; Antonio Napolitano; Claudia Scaringi; Giuseppe Minniti; Alessandro Bozzao
Journal:  Br J Radiol       Date:  2016-08-09       Impact factor: 3.039

Review 5.  Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

Authors:  N Soni; M Ora; N Mohindra; Y Menda; G Bathla
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

6.  Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.

Authors:  Ryan S Youland; Deanna H Pafundi; Debra H Brinkmann; Val J Lowe; Jonathan M Morris; Bradley J Kemp; Christopher H Hunt; Caterina Giannini; Ian F Parney; Nadia N Laack
Journal:  J Neurooncol       Date:  2018-01-13       Impact factor: 4.130

Review 7.  Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors.

Authors:  Csaba Juhász; Shalini Dwivedi; David O Kamson; Sharon K Michelhaugh; Sandeep Mittal
Journal:  Mol Imaging       Date:  2014       Impact factor: 4.488

8.  Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.

Authors:  Lisbeth Marner; Michael Lundemann; Astrid Sehested; Karsten Nysom; Lise Borgwardt; René Mathiasen; Peder S Wehner; Otto M Henriksen; Carsten Thomsen; Jane Skjøth-Rasmussen; Helle Broholm; Olga Østrup; Julie L Forman; Liselotte Højgaard; Ian Law
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 12.300

9.  Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.

Authors:  Norbert Galldiks; Maximilian Niyazi; Anca L Grosu; Martin Kocher; Karl-Josef Langen; Ian Law; Giuseppe Minniti; Michelle M Kim; Christina Tsien; Frederic Dhermain; Riccardo Soffietti; Minesh P Mehta; Michael Weller; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

10.  Dynamic 18F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology.

Authors:  Maria R Ponisio; Jonathan E McConathy; Sonika M Dahiya; Michelle M Miller-Thomas; Keith M Rich; Amber Salter; Qing Wang; Pamela J LaMontagne; Gloria J Guzmán Pérez-Carrillo; Tammie L S Benzinger
Journal:  Neurooncol Pract       Date:  2020-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.